MONMOUTH
JUNCTION, N.J., May 2, 2022
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a
leader in the treatment of life-threatening conditions in the
intensive care unit and cardiac surgery using blood purification,
announced that the Company has been awarded a new preferred
supplier agreement for CytoSorb® with the Asklepios Group
(Asklepios), one of the largest private hospital operators in
Germany, following the majority
acquisition of RHÖN‑KLINIKUM AG in 2020.
CytoSorbents has entered into a 3-year preferred supplier
agreement with Asklepios, making CytoSorb available without
restrictions to all of the approximate 170 healthcare facilities
across 14 states throughout Germany that Asklepios operates. This includes
Asklepios Klinik St. Georg in Hamburg,
Germany, which pioneered the use of CytoSorb to remove
antithrombotic drugs during cardiothoracic surgery, and is
well-known for their seminal publication on CytoSorb use for this
application during emergency cardiac surgery in patients at high
risk of bleeding.
Dr. Christian Steiner, Executive
Vice President, Sales and Marketing of CytoSorbents stated, "We are
excited to announce this agreement with Asklepios, as we are now
their preferred supplier of hemoadsorption technology. With this
new agreement, CytoSorbents now has preferred supplier agreements
with the three largest hospital chains in Germany, providing an opportunity to further
grow our business. These privately owned hospital chains are always
seeking value-added therapies that provide both clinical and
economic benefit to ensure the highest quality medical care for
their patients while supporting profitable operations. I am
convinced CytoSorb is helping these hospital chains achieve both
objectives."
About Asklepios Group
Asklepios was established in
1985 and is now a leading private operator of hospitals in
Germany. Asklepios' business
activities have always been aimed at providing future-oriented
medicine for patients based on the highest quality standards.
Asklepios aspires to shape the future of medicine. One key to this
lies also in digitalization. The Asklepios vision of a completely
integrated digital healthcare group is summed up with the term
"Digital HealthyNear". The Group currently has around 170
healthcare facilities throughout Germany represented in 14 German federal
states functioning as a nationwide network for holistic healthcare
provision. These include acute care hospitals of all different care
levels, university hospitals, specialist hospitals, prevention and
aftercare, rehabilitation clinics and medical centers. In the
2021 financial year over 3.5 million patients were treated at the
Asklepios Group's facilities. The company has more than 67,000
employees. For more information consult www.asklepios.com.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of
life-threatening conditions in intensive care and cardiac surgery
using blood purification. Its flagship
product, CytoSorb®, is approved in the European Union with
distribution in more than 70 countries around the world as an
extracorporeal cytokine adsorber designed to reduce the "cytokine
storm" or "cytokine release syndrome" seen in common critical
illnesses that may result in massive inflammation, organ failure
and patient death. These are conditions where the risk of
death can be extremely high, yet few to no effective treatments
exist. CytoSorb is also being used during and after
cardiothoracic surgery to remove inflammatory mediators that can
lead to post-operative complications, including multiple organ
failure. More than 162,000 cumulative CytoSorb devices have
been utilized as of December 31,
2021. CytoSorb was originally introduced into the European
Union under CE-Mark as a first-in-kind cytokine adsorber.
Additional CE-Mark label expansions were received for the removal
of bilirubin and myoglobin in clinical conditions such as liver
disease and trauma, respectively, and
both ticagrelor and rivaroxaban during
cardiothoracic surgery. CytoSorb has also received FDA
Emergency Use Authorization in the United States for
use in adult critically ill COVID-19 patients with imminent or
confirmed respiratory failure. The DrugSorb™-ATR
Antithrombotic Removal System, which is based on the same polymer
technology as CytoSorb, has also been
granted FDA Breakthrough Designation for the removal
of ticagrelor, as well as FDA Breakthrough
Designation for the removal of the direct oral anticoagulant
(DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass
circuit during urgent cardiothoracic surgery. The Company has
initiated two FDA approved pivotal trials designed to support U.S.
marketing approval of DrugSorb-ATR. The first is the
120-patient, 30 center STAR-T (Safe
and Timely Antithrombotic Removal-Ticagrelor)
randomized, controlled trial evaluating the ability of
intraoperative DrugSorb-ATR use to reduce perioperative bleeding
risk in patients on ticagrelor undergoing cardiothoracic
surgery. The second is the 120-patient, 30
center STAR‑D (Safe
and Timely Antithrombotic Removal-Direct
Oral Anticoagulants) randomized, controlled trial, evaluating the
intraoperative use of DrugSorb–ATR to reduce perioperative bleeding
risk in patients undergoing cardiothoracic surgery on direct oral
anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received
non-dilutive grant, contract, and other funding of more
than $39.5 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The
Company has numerous marketed products and products under
development based upon this unique blood purification technology
protected by many issued U.S. and international patents and
registered trademarks, and multiple patent applications pending,
including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™,
HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™,
DrugSorb™-ATR, ContrastSorb, and others. For more
information, please visit the Company's websites
at www.cytosorbents.com and www.cytosorb.com or
follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, future targets and outlooks
for our business, expectations regarding the future impacts of
COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and contentions and
are not historical facts and typically are identified by use of
terms such as "may," "should," "could," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential,"
"continue" and similar words, although some forward-looking
statements are expressed differently. You should be aware that the
forward-looking statements in this press release represent
management's current judgment and expectations, but our actual
results, events and performance could differ materially from those
in the forward-looking statements. Factors which could cause or
contribute to such differences include, but are not limited to, the
risks discussed in our Annual Report on Form 10-K, filed with the
SEC on March 10, 2022, as updated by
the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Terri Anne Powers
Vice
President, Investor Relations
and Corporate
Communications
(732)
482-9984
tpowers@cytosorbents.com
U.S. Public
Relations Contact:
Eric Kim Rubenstein Public
Relations
212-805-3052 ekim@rubensteinpr.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytosorbents-awarded-preferred-supplier-agreement-with-asklepios-one-of-the-largest-private-hospital-operators-in-germany-301536980.html
SOURCE CytoSorbents Corporation